Abstract. Mortality after initial diagnosis of lung cancer is higher than from any other cancer. Although mutations in several genes, such as EGFR and K-ras, have been associated with clinical outcome, technical complexity, cost and time have rendered routine screening prohibitive for most lung cancer patients prior to treatment. In this study, using both novel and established technologies, we developed a clinically practical assay to survey the status of three frequently mutated genes in lung cancer (EGFR, K-ras and TP53) and two genes (BRAF and β-catenin) with known hotspot mutations in many other cancers. A single 96-well plate was designed targeting a total of 14 fragments (16 exons) from EGFR, K-ras, TP53, BRAF and β-catenin. In 96 lung adenocarcinoma patients, the mutation frequencies of three major genes (EGFR, K-ras and TP53) were between 21-24%. Fifty-six out of 96 (58%) patients had a mutation in at least one of the five genes. K-ras mutations positively correlated with smoking pack-years (p=0.035). EGFR mutations were frequent in never-smokers (p=0.0007), Asians (p=0.0204) and non-stage I lung cancer (p=0.016). There was also a trend towards an association between the presence of any mutation and improved recurrence-free survival (p=0.070). We demonstrate that our novel multigene mutation assay technology can rapidly and cost-effectively screen for mutations in lung adenocarcinoma. This screening assay can be used in the clinical setting for the large-scale validation of prognosis and/or predicting therapeutic response so that the majority of lung cancer patients can benefit from leveraging up-to-date knowledge on how mutation profiles may influence treatment options.
Introduction
Lung cancer is the leading cause of cancer mortality in both men and women in the US, taking more lives each year than breast, prostate, colon and pancreatic cancers combined (1) . Personalized medicine, or the tailoring of treatments to heterogeneous diseases based on the unique biological profile of each individual, has not yet gained widespread clinical acceptance in lung cancer. Ideally, personalized therapies would be provided to early-stage lung cancer patients in order to dramatically decrease the likelihood of recurrence or for administration of anti-cancer drugs contra-indicated for specific genetic subtypes of lung cancer. Several key genes known to be mutated in lung cancer have been associated with patient prognosis and/or response to clinical therapy. It is already known, for example, that lung adenocarcinoma patients with an EGFR mutation usually show better response to tyrosine kinase inhibitors (TKIs), such as gefitinib or erlotinib (2) . In contrast to EGFR, lung cancer patients with K-ras mutations display primary resistance to TKIs or chemotherapy (3) . EGFR mutations tend to be more common in non-smoker and East-Asian females while K-ras mutations are frequently found in smokers (4, 5) . Thus, an EGFR mutation is usually considered a good prognostic marker while a K-ras mutation is considered a bad prognostic marker (6) . TP53 mutations are among the most frequently screened in human cancer; however, the prognostic value of TP53 in lung cancer remains controversial. Certain studies have reported that TP53 mutations are associated with worse prognosis; however, these findings are inconsistent (7) . Although a few studies have screened multiple genes in lung cancer patients, the correlation between the sum of different mutations and patient prognosis remains unclear (8) (9) (10) .
Despite the known clinical associations of EGFR and K-ras mutations in lung cancer, and notwithstanding their significance in predicting prognosis or selecting therapeutic regimens, technical complexities, cost and delayed results (often days to weeks) have prevented clinical screening for somatic mutations from becoming routine. Much effort has gone into developing simple and high-throughput mutation screening technology, but the common use of radioactive isotopes and relatively low sensitivity has been reported as problematic (11, 12 Calculating the composite effects of key mutations using NGS will require both testing and validation so that key or driving mutations can be selected from around 20,000 candidates (13) (14) (15) . Ideally, key driver genes/mutations would be identified first using different mutation screening technologies so that a low-cost and simple assay for these genes or mutations can be developed for clinical use. Such a fast and reliable technology would rapidly assay commonly found somatic mutations to potentially significantly alter lung cancer prognosis and survival.
We targeted three of the most frequently mutated genes in lung cancer and two additional genes that have been reported to be widely mutated in many different types of cancer. In lung cancer, the combined frequency of mutations in any of these five genes amounts to more than 50% of cases.
Materials and methods
Patient samples. The Committee on Human Research (CHR) of the University of California San Francisco (UCSF) reviewed and approved the application for the collection of blood, sputum and tissue samples from patients with suspected or biopsyproven thoracic malignancies (approval number: 10-03352). All samples were collected under the IRB approval granted by the CHR and written informed consents were obtained from all patients in this study.
DNA extraction from frozen lung adenocarcinoma tissues. DNA was extracted from 96 adenocarcinoma patients using either the Qiagen DNA mini kit (Qiagen) or the phenol/ chloroform method. For the phenol/chloroform method, the tissue was ground in liquid nitrogen using a mortar and pestle and then incubated in DNA lysis buffer and proteinase K overnight at 56˚C. The incubated solution was mixed with the same volume of phenol-chloroform solution [UltraPure™ phenol:chloroform:isoamyl alcohol (25:24:1, v/v), Invitrogen] and then centrifuged. The top layer of the solution was mixed with the same volume of isopropyl alcohol. After centrifugation, the DNA pellet was washed using 70% ethanol, dried and eluted in distilled water (DW). DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples was extracted using the Epicentre MasterPure FFPE DNA Extraction kit. The starting material was six 10-µm thick slices from a pathology block of FFPE tissue. These samples were incubated at 65˚C in tissue and cell lysis solution with proteinase K and then treated with RNaseA. Nucleic acids were precipitated and purified according to the standard Epicentre protocol and the final elution was into 50 µl of nuclease-free water. The clinical characteristics of the 96 adenocarcinoma patients are shown in Table I .
Development of the mutation assay with five genes. Three of the most frequently mutated genes (K-ras, EGFR and TP53) in lung cancer and two genes reported to be widely mutated in many different types of cancer (BRAF and β-catenin) were selected for the development of the mutation assay. A total of 14 fragments covering 16 exons of the five genes were designed to be amplified under the same conditions. Primers were designed using the Primer3 software and then tested and optimized. PCR primer sequences are shown in Table II . Amplification was performed at 58˚C using 20 ng of genomic DNA, 10X PCR buffer supplemented with 1.5 mM MgCl 2 , 10 pmol of each primer, 50 mM of each dNTP, and 0.2 units of Taq polymerase (Qiagen) in a total volume of 25 µl. To prepare the ready-to-use mutation assay, master mixes were prepared for each primer pair and 23 µl were aliquoted into individual wells of a 96-well plate and frozen at -20˚C until use. Pre-made plates stored for up to two weeks did not produce different results from plates that were stored for shorter amounts of time. PCR products were subjected to agarose gel electrophoresis (2% agarose) to confirm amplification. The PCR products were cleaned up using 1 µl of SAP (1 unit/µl), 0.1 µl of ExoI enzyme (10 units/ µl), 1 µl of 1X PCR buffer, 2.4 µl of 10X NEB buffer (type 3), 5 µl of the PCR product, and 15 µl of water. For samples with a less intense band on the agarose gel, the amount of PCR product used was increased while the amount of water used was decreased. The reaction was incubated in a thermal cycler for 10 min at 25˚C, 60 min at 37˚C, and 15 min at 95˚C. The cleaned PCR product (5 µl) was added to 1 µl of primer and 9 µl of water and this was then sent to a commercial sequencing company to be sequenced. Bi-directional sequencing was performed using the Taq dideoxy terminator cycle sequencing kit and an ABI 3730 DNA sequencer (Applied Biosystems, Foster City, CA, USA). Each plate took approximately 24 h to amplify and sequence, with a mutation report generated for each patient at the end of the 24-h period. Sixteen wells were used for each patient, allowing up to six patients to be simultaneously run on a single 96-well plate (Fig. 1) .
Statistical analysis.
Associations between dichotomous and categorical patient clinicopathological characteristics and specific gene mutations were analyzed using the Chi-square test for dichotomous variables and a trend test for categorical variables. Continuous clinicopathological variables (age, tumor size and smoking pack-years) were regressed on the number and type of gene mutation using univariate linear regression and tested using a t-statistic. For all statistical tests, a twotailed α-value of 0.05 was considered to indicate statistically significant differences. To determine recurrence-free survival, we used a right-censored dataset in which tumor recurrence or patient death were counted as events. Comparison between five-year recurrence-free survival by mutation status was tested using the Wilcoxon (Breslow) test. Hospital records including radiological and pathological reports as well as clinical notes were examined for evidence of recurrence. Vital status was obtained by querying the Social Security Death Master File (http://www.ssdmf.com). Five-year Kaplan-Meier survival curves were plotted for patients with and without mutations. STATA/MP 11.1 was used for all statistical analyses (StataCorp LP, College Station, TX).
Results
Mutations of five genes in the assay. A total of 16 exons from five genes (K-ras, EGFR, TP53, BRAF and β-catenin) were simultaneously amplified. The mutation assay is shown in Fig. 1 . Three lung cancer cell lines (H1650, A549 and H460) with known mutations were used as the positive controls. The mutation frequencies and the amplified exon information of the five genes are shown in Fig. 2a . The mutation frequencies for EGFR, TP53 and K-ras were between 21-24%. Only two mutations were identified in BRAF and one mutation was identified in β-catenin. In 56 out of the 96 (58%) adenocarcinoma patients, there was a mutation in at least one of the five genes. An EGFR L858R mutation was found in 18% (10/56) and EGFR exon 19 deletion mutations were found in 9% (5/56) of the total mutations. K-ras codon 12 and 13 mutation frequencies were 36% (20/56) and 3% (2/56), respectively (Fig. 2e) . Other mutations or variants, such as nonsense mutations and polymorphisms, were also detected in this assay.
Mutations and clinical outcome. The mutation data were compared with the clinicopathological characteristics of our (Table III) .
Prognosis prediction based on mutation status. There was a trend toward the presence of any mutation and improved prognosis. Patients with any mutation showed improved fiveyear recurrence-free survival vs. patients without a mutation (p=0.070) (Fig. 3) . No single gene mutation was significantly associated with patient outcome. were designed to be analyzed in one plate under the same conditions. A total of 14 fragments covering 16 exons of five genes were designed in this assay. Short exons, TP53 exons 3/4 and 8/9, were designed to be amplified together in one fragment. In a regular 96-well plate, six different patient DNAs can be analyzed in one plate, which will provide high-throughput mutation screening in the clinic. 
Sensitivity and specificity assay using additional primary tissues, FFPE samples and serially diluted cell line.
We selected an additional 20 tissue samples that were previously analyzed using a conventional sequencing method to examine the sensitivity and specificity of the developed mutation assay. Five samples each containing either a K-ras, EGFR, or TP53 mutation plus another five wild-type samples were analyzed in a blind manner. All mutations were clearly detected in the 15 samples containing mutations and no mutation was found in the five wild-type samples (data not shown). We also tested eight different FFPE samples that had mutation data from the corresponding primary tissue in a blind manner. The mutations in all eight FFPE samples were identical to those detected in the primary tissues (Fig. 4) . We also serially diluted the H1650 cell line, which contains an EGFR mutation, with water and found that the EGFR deletion mutation was clearly detected even at the picogram level (Fig. 5) .
Discussion
While lung cancer discovered early is potentially curable, patients rarely exhibit clinical symptoms at this stage of their disease. The majority of cases (60-70%) are diagnosed at an advanced, often incurable, stage, desperately underscoring the need for improved clinical outcomes based on individual and personalized genetic information. One example of a personalized approach is the prediction of anti-cancer drug treatment response based on the mutation statuses of EGFR and K-ras (6) . Because EGFR and K-ras mutation status is predictive of response to chemotherapy, assessing the mutation status of these two key genes in every lung cancer patient to direct the course of major treatment decisions is likely to improve the overall prognosis of lung cancer patients. TP53 is also frequently mutated in lung cancer; however, the association between TP53 mutations and clinical outcome has not been clearly established. The unknown significance of TP53 mutations could be either due to a biological reason or due to unavailability of sufficient research data. BRAF is mutually exclusive with K-ras and a promising anti-cancer target in many types of cancers (16) . The hotspot mutations in the same exon (exon 3) have also been reported in most human cancer types in β-catenin. To date it has been impractical to screen for mutations of multiple genes in the clinical setting due to time and cost constraints, highlighting the need for an inexpensive, rapid and reliable mutation screening assay. To this end, we developed a practical multigene mutation assay that may be prognostic of patient outcome. As a pre-designed 'ready-touse' assay, this assay can be completed from DNA extraction to the final mutation report within 24 h. If any novel key mutation in lung cancer patients is identified in NGS or another analysis, it can easily be added to our developed assay without any major change in the protocol.
We screened approximately 100 lung adenocarcinoma patients using this multigene mutation assay. When comparing genetic mutations to the clinicopathological characteristics of our patient cohort, we observed many of the well-established associations previously described in lung cancer research (4, (17) (18) (19) . K-ras mutations positively correlated with smoking (p=0.035) while EGFR mutations were more common in never-smokers (p=0.0007). These well-established associations validate the compatibility of our new fast multigene mutation assay with conventional single gene mutation screening methods. Different associations between genes and smoking status may suggest that a multigene approach to mutation screening rather than a single-gene approach is desirable to investigate the association between genes and and clinical findings, although further study with a larger sample cohort is required to investigate this issue.
As FFPE tissue is the most readily available tissue substrate in clinical practice, we also tested DNA extracted from eight FFPE specimens, whose primary tissues were analyzed and for which mutation information was available, and were able to validate the stability of the assay in DNA extracted from FFPE specimens (Fig. 4) . Moreover, in the serial dilution analysis of H1650, even picogram amounts of DNA could be used for the mutation screening (Fig. 5) . Including TP53 mutations, approximately 60% of the patients had a mutation in any of the three genes (EGFR, K-ras and TP53). Hotspot mutations of EGFR (L858R and exon 19 deletion mutations) and K-ras codon 12 and 13 mutations composed 66% (37/56) of the total mutations or 39% (37/96) of the patients. A quick and simple mutation screening for these four different mutations can give us approximately 40% sensitivity in early-stage lung cancer patients. Although K-ras mutations have been reported to be associated with bad prognosis and EGFR mutations with good prognosis, no single gene was significantly associated with disease or recurrencefree survival (6) . Our data suggest that a mutation in any of the five genes is associated with better recurrence-free survival (p=0.07, Fig. 3 ). It is not clear how mutant tumor cells rather than non-mutant tumor cells contribute to improved patient recurrence-free survival. Although it is still controversial, TP53 mutations have been reported to be associated with worse prognosis. However, this is not clear as the mutation effect of TP53 is complex and there are several different types of mutations in TP53, such as dominant-negative effect or gain-of-function mutations (20) . Although the sample size in our study was small and further validation should be performed to validate this association, our results suggest that the combination or the sum of mutations from multiple key genes, not a single gene, could be used for markers of not only early detection, but also patient prognosis. We believe the sum of mutations or polymorphisms, rather than a single gene or variation, may ultimately prove to be most useful in accurately predicting clinical outcomes. Taken together, we developed a practical multigene mutation screening assay containing five genes for lung adenocarcinoma patients. An interesting trend towards increased recurrence-free survival with at least one gene mutation was also noted. As this assay is designed for the analysis of a large number of patients within 24 h, this assay may ultimately be used on biopsy specimens of cancer patients before major treatment decisions or for noninvasive screening in the clinical setting.
